Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06277466

Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls

In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression.

Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

25 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

China, Jiangsu, Department of Endocrinology

Xuzhou, 221006, China

Location status: Recruiting

Location contact

Hongwei Ling, MD

CONTACT

[email protected]

18052268607

Renguo Chen, MD

PRINCIPAL_INVESTIGATOR

Yuhan Huang, MD

SUB_INVESTIGATOR

About this study

The primary objective of this study was to investigate the changes of the expression of T2DM susceptible genes (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) in participants (newly diagnosed T2DM patients and controls) after gene mutation.

Secondly, the expression differences of T2DM susceptible genes in T2DM patients with different genotypes were compared, and the relationship between the expression differences and clinicopathological characteristics of T2DM patients was analyzed.

Participants (newly diagnosed T2DM patients and healthy subjects) were screened from the department of endocrinology and health management center, whose fresh peripheral blood were collected. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected in the department of general surgery. The DNA genome was extracted for genotyping, and then the expression levels of T2DM related susceptibility genes under different genotypes were detected by ELISA kits, PCR, WB,HE staining, IHC staining, ect.

The basic information of T2DM patients was collected, including demographic characteristics, physiological and biochemical data.Then investigators further compared the differences in the expression of susceptible genes between newly diagnosed T2DM patients and controls.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • no drug therapy; 25 to 70 years old; Hemoglobin A1c (HbA1c) 7%-12%; BMI 20-35 kg/m2; Stable body weight (≤10% change within 3 months)(For newly diagnosed patients with T2DM).
  • 25 to 60 years old; BMI 19-26 kg/m2; in good health, with no abnormalities of motor system, digestive system, respiratory system, urogenital system, blood system, circulatory system, nervous/mental system, endocrine system, etc(For healthy subjects).
  • 20-80 years old; surgical resection of part or all of the pancreas; pancreatic lesions confirmed by enhanced CT or magnetic resonance (MR) examination or confirmed by intraoperative and postoperative pathology(For the patients in general surgical).

Exclusion criteria

  • had taken antidiabetic drugs;
  • had a history of pancreatic surgery;
  • Complicated with severe organ lesions;
  • Long-term use of drugs that affect pancreatic function.

Treatment and study plan

Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs

Drug

Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.

Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs

Drug

The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.

In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.

Primary outcomes

  1. Detection of T2DM susceptibility gene expression in newly diagnosed T2DM patients

    Time frame: 1 month after fresh sample collection

    To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of newly diagnosed T2DM patients and compared with those in healthy subjects.

  2. Detection of T2DM susceptibility gene expression in controls

    Time frame: 1 month after fresh sample collection

    To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of controls and compared with those in newly diagnosed T2DM patients.

  3. Correlation between T2DM susceptibility gene expression and clinicopathological features

    Time frame: 6 months after obtaining the clinicopathological results

    Incidence of clinical pancreatic diseases under expression differences in T2DM susceptibility genes

Secondary outcomes

  1. Baseline BMI of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline BMI of newly diagnosed with T2DM patients

  2. Baseline waist hip ratio (WHR) of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline WHR of newly diagnosed with T2DM patients

  3. Baseline fasting plasma glucose (FPG) of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline FPG of newly diagnosed with T2DM patients

  4. Baseline HbA1c of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline HbA1c of newly diagnosed with T2DM patients

  5. Baseline TC of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline TC of newly diagnosed with T2DM patients

  6. Baseline TG of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline TG of newly diagnosed with T2DM patients

  7. Baseline HDL-C of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline HDL-C of newly diagnosed with T2DM patients

  8. Baseline LDL-C of newly diagnosed with T2DM patients with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline LDL-C of newly diagnosed with T2DM patients

  9. Baseline BMI of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline BMI of controls

  10. Baseline WHR of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline WHR of controls

  11. Baseline FPG of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline FPG of controls

  12. Baseline HbA1c of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline HbA1c of controls

  13. Baseline TC of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline TC of controls

  14. Baseline TG of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline TG of controls

  15. Baseline HDL-C of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline HDL-C of controls

  16. Baseline LDL-C of controls with different genotypes

    Time frame: 1 month of completion for individual screening

    Baseline LDL-C of controls

Study contacts

Contact information is provided by the study sponsor or research team.

Tao Wang, Ph.D

CONTACT

[email protected]

13815344640

Xiaoxing Yin, Ph.D

CONTACT

[email protected]

13605218523

Sponsors and collaborators

Lead sponsor

The Affiliated Hospital of Xuzhou Medical University

Other

Registry information

Official study title

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Feb 26, 2024
Registry last updated
Feb 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.